This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (165)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kenneth V. I. Rolston, MD; Peter Berkey, MD; Gerald P. Bodey, MD; Elias J. Anaissie, MD; Nancy M. Khardori, MD; Jai H. Joshi, MD; Michael J. Keating, MD; Frankie A. Holmes, MD; Fernando F. Cabanillas, MD; Linda Elting, DPH

Arch Intern Med. 1992;152(2):283-291.

Abstract
Background.—
Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile. The availability of broadspectrum antibiotics such as ceftazidime and imipenem has made it possible to initiate therapy with a single agent (monotherapy). The objectives of this trial were to compare ceftazidime and imipenem as single agents for the therapy of febrile episodes in neutropenic patients and to ascertain whether the addition of an aminoglycoside (amikacin) to either of these agents would provide an advantage.

Methods.—
A prospective clinical trial was conducted in which eligible neutropenic patients with cancer were randomized to one of four treatment arms: ceftazidime alone; imipenem alone; ceftazidime plus amikacin; and imipenem plus amikacin. Efficacy analysis was done for 750 assessable episodes. A multivariate logistic-regression analysis was also performed to examine the unique contribution of various prognostic factors.

Results.—
The overall response rates were 76% with imipenem plus amikacin, 72% with imipenem, 71% with ceftazidime plus amikacin, and 59% with ceftazidime alone. Single-organism gram-positive infections occurred in 101 of 750 episodes. Without a change in antibiotics, the response rates were 50% with imipenem, 40% with imipenem plus amikacin, 39% with ceftazidime plus amikacin, and 38% with ceftazidime. Most responded to vancomycin or other antibiotics, and the mortality associated with gram-positive infections was only 5%. Regardless of the antibiotic regimen, the majority of uncomplicated gramnegative infections responded to therapy and the majority of complicated gram-negative infections failed to respond. Multivariate logistic-regression analysis showed that recovery of the neutrophil count was the most favorable prognostic factor in a patient's response to infection, whereas the presence of gram-positive infection, acute leukemia, pulmonary or enteric infection, and therapy with ceftazidime were unfavorable factors.

Conclusions.—
Single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer.

(Arch Intern Med. 1992;152:283-291)

Author Affiliations
From the Section of Infectious Diseases, Department of Medical Specialties, The University of Texas M. D. Anderson Cancer Center, Houston.

Footnotes
Accepted for publication October 14, 1991.

Reprint requests to Section of Infectious Diseases (Box 47), The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (Dr Rolston).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Two decades of imipenem therapy
Rodloff et al.
J Antimicrob Chemother 2006;58:916-929.
ABSTRACT | FULL TEXT  

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials
Paul et al.
J Antimicrob Chemother 2006;57:176-189.
ABSTRACT | FULL TEXT  

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer
Mitchell et al.
Ann Oncol 2004;15:585-589.
ABSTRACT | FULL TEXT  

Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer
Fleischhack et al.
J Antimicrob Chemother 2001;47:841-853.
ABSTRACT | FULL TEXT  

Prospective evaluation of a policy of early discontinuation of antibiotics and discharge from hospital in children with cancer who develop fever
Wiernikowski et al.
J Oncol Pharm Pract 2001;6:131-137.
ABSTRACT  

Infections in the Neutropenic Patient-- New Views of an Old Problem
Donowitz et al.
ASH Education Book 2001;2001:113-139.
ABSTRACT | FULL TEXT  

Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever
Giamarellou et al.
Antimicrob. Agents Chemother. 2000;44:3264-3271.
ABSTRACT | FULL TEXT  

Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial
Feld et al.
JCO 2000;18:3690-3698.
ABSTRACT | FULL TEXT  

Time to Clinical Response: An Outcome of Antibiotic Therapy of Febrile Neutropenia With Implications for Quality and Cost of Care
Elting et al.
JCO 2000;18:3699-3706.
ABSTRACT | FULL TEXT  

The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
Klastersky et al.
JCO 2000;18:3038-3051.
ABSTRACT | FULL TEXT  

A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy
Erjavec et al.
J Antimicrob Chemother 2000;45:843-849.
ABSTRACT | FULL TEXT  

Recent Experience With Pseudomonas aeruginosa Bacteremia in Patients With Cancer: Retrospective Analysis of 245 Episodes
Chatzinikolaou et al.
Arch Intern Med 2000;160:501-509.
ABSTRACT | FULL TEXT  

Fever in Immunocompromised Patients
Serody and Pizzo
NEJM 2000;342:217-218.
FULL TEXT  

In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa
Oie et al.
J Antimicrob Chemother 1999;44:689-691.
ABSTRACT | FULL TEXT  

An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients
Hoffken et al.
J Antimicrob Chemother 1999;44:367-376.
ABSTRACT | FULL TEXT  

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy
Kern et al.
NEJM 1999;341:312-318.
ABSTRACT | FULL TEXT  

Comparison of Activities of Broad-Spectrum beta -Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers
Diekema et al.
Antimicrob. Agents Chemother. 1999;43:940-943.
ABSTRACT | FULL TEXT